Effectiveness of Combining Antiobesity Medication With an Employer-Based Weight Management Program for Treatment of Obesity-Reference-Cited by-同舟云学术

Effectiveness of Combining Antiobesity Medication With an Employer-Based Weight Management Program for Treatment of Obesity

Published:2021-07-13 Issue:7 Volume:4 Page:e2116595
ISSN:2574-3805
Container-title:JAMA Network Open
language:en
Short-container-title:JAMA Netw Open

Author:

Pantalone Kevin M.¹,Smolarz B. Gabriel²,Ramasamy Abhilasha²,Baz Hecht Merav²,Harty Brian J.³,Rogen Bruce⁴,Griebeler Marcio L.¹,Borukh Elena¹,Young James B.⁵,Burguera Bartolome¹

Affiliation:

1. Endocrinology and Metabolism Institute, Cleveland Clinic, Cleveland, Ohio

2. Novo Nordisk Inc, Plainsboro, New Jersey

3. HealthCore, Inc, Watertown, Massachusetts

4. Cleveland Clinic Employee Health Plan, Cleveland, Ohio

5. Cleveland Clinic Executive Administration, Cleveland, Ohio

Publisher

American Medical Association (AMA)

Subject

General Medicine

Link

https://jamanetwork.com/journals/jamanetworkopen/articlepdf/2781926/pantalone_2021_oi_210502_1625605093.65131.pdf

Reference40 articles.

1. Projected U.S. state-level prevalence of adult obesity and severe obesity.;Ward;N Engl J Med,2019

2. Health effects of overweight and obesity in 195 countries over 25 years.;Afshin;N Engl J Med,2017

3. American Association of Clinical Endocrinologists’ position statement on obesity and obesity medicine.;Mechanick;Endocr Pract,2012

4. 2013 AHA/ACC/TOS guideline for the management of overweight and obesity in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and The Obesity Society.;Jensen;J Am Coll Cardiol,2014

Cited by 16 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Work loss among privately insured employees with overweight and obesity in the United States;Obesity Science & Practice;2024-07-08

2. An Obesity-Centric Approach with and Without Anti-Obesity Medications Compared to the Usual-Care Approach to Management of Patients with Obesity and Type 2 Diabetes in an Employer Setting: A Pragmatic Randomized Controlled Trial (EMPOWER-T2D);Diabetes Therapy;2024-04-04

3. Effectiveness and safety of drugs for obesity;BMJ;2024-03-25

4. Nanomodulator-Mediated Restructuring of Adipose Tissue Immune Microenvironments for Antiobesity Treatment;ACS Nano;2024-03-18

5. Liraglutide 3.0 mg in the treatment of adults with obesity and prediabetes using real‐world UK data: A clinical evaluation of a multi‐ethnic population;Clinical Obesity;2024-03-04